What Is a Certificate of Analysis?

A certificate of analysis, usually shortened to COA, is a document summarizing analytical testing performed on a defined sample. Ideally, it identifies the sample, the batch or lot, the methods used, the results obtained, the specifications or acceptance criteria applied, the laboratory that performed the work, and the date the testing was completed.

A COA should be viewed as a structured report about a particular sample under particular test conditions. It is not a universal guarantee. Its strength depends on the quality of the sample, the relevance of the methods, the competence and independence of the laboratory, the validity of the analytical procedures, the integrity of the data, and whether the tested sample is actually representative of the material being offered.

A COA is evidence, not a conclusion

Different tests answer different questions. For example, reversed-phase HPLC with ultraviolet detection may estimate the proportion of detected chromatographic components represented by the main peak. Mass spectrometry may support molecular identity by showing that the observed mass is consistent with the expected peptide. A quantitative assay may estimate how much peptide is present. Sterility and bacterial endotoxin tests address entirely different quality attributes.

A document containing only a peptide name and “Purity: 99.4%” may look reassuring, but it leaves major questions unanswered. A scientifically meaningful assessment usually requires a combination of complementary tests rather than a single number.

The Five Questions Every Peptide COA Should Help Answer

Purity and Quantity Are Not the Same

This is the most important distinction in the entire article. A peptide can produce a high chromatographic purity result and still contain less peptide than the labeled amount. Conversely, a vial can contain approximately the expected total peptide quantity while also containing a meaningful proportion of related impurities.

Why 99% purity can coexist with underfilling

Imagine a vial labeled as containing 10 mg of a peptide. A laboratory analyzes a sample and reports 99.2% HPLC purity. That number may indicate that 99.2% of the integrated UV-detected chromatographic peak area belonged to the main peak. It does not necessarily show that 10 mg of peptide was present. The vial could theoretically contain 7 mg of highly pure peptide, 10 mg, or another amount unless a validated or otherwise fit-for-purpose quantitative content test was performed.

Why the dried cake cannot answer the question

The visible size of a lyophilized cake is not a reliable measurement of peptide mass. Excipients, buffers, salts, moisture, freezing conditions, vial geometry, concentration before drying, and the lyophilization cycle can dramatically change cake volume and appearance. A larger cake may contain more bulking agent rather than more peptide. A very small or nearly invisible deposit may still contain the stated peptide amount if little excipient was used.

Anatomy of a Credible Peptide COA

A professional layout alone does not make a COA trustworthy. Review the document field by field and determine whether the information creates a traceable, technically coherent record.

Specifications versus results

A result is what the laboratory measured. A specification is the predefined acceptance criterion used to decide whether the result is acceptable. For example:

Specifications should be established before the result is known. A pass/fail statement is less meaningful when the acceptance criterion is hidden, altered after testing, or chosen solely to make the sample pass.

How to Read HPLC or UPLC Results

High-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC or UHPLC) separate components based on how they interact with a stationary phase and a flowing mobile phase. In peptide testing, reversed-phase chromatography is commonly used to examine the main peptide and related components.

What the chromatogram shows

A chromatogram plots detector response against time. Each detected component may appear as a peak. The time at which a peak appears is its retention time. The integrated area under a peak is often used to estimate its relative contribution to the total detected chromatographic area.

What “area percent” actually means

Many peptide COAs report purity using area normalization:

This is a relative chromatographic calculation. It generally assumes that the included components respond comparably at the selected detection wavelength, an assumption that may not always hold. Some impurities absorb ultraviolet light differently from the main peptide. Compounds with little or no response at the chosen wavelength may be underestimated or missed. Nonvolatile salts, water, some excipients, and certain contaminants may not appear as meaningful peaks in the same method.

Questions to ask about an HPLC result

• Was the method intended for identity, purity, assay, or more than one purpose?
• Which detector and wavelength were used?
• Was a suitable peptide reference standard analyzed?
• Did the report include the full chromatogram and integration table?
• Were all relevant peaks integrated, or were some excluded?
• What was the reporting threshold for small peaks?
• Was system suitability demonstrated?
• Was the method shown to separate known related impurities and degradation products?
• Was the result reported as area percent, weight percent, concentration, or assay?

Retention time is supportive, not definitive by itself

A peak appearing at approximately the same retention time as a known standard supports identification, but unrelated compounds can sometimes coelute or produce similar retention behavior. Identity is stronger when chromatographic comparison is paired with an orthogonal technique such as mass spectrometry.

Why a perfect-looking chromatogram may still be incomplete

Chromatography only reveals what the method can separate and what the detector can detect under the chosen conditions. A narrow monitoring window, unsuitable wavelength, poor resolution, high reporting threshold, overloaded column, or selective integration can create an overly reassuring picture. This is why raw-data context and method suitability matter more than the beauty of the graph.

How to Read Mass Spectrometry Results

Mass spectrometry measures ions according to their mass-to-charge ratio, written as m/z. For peptides, electrospray ionization commonly produces several charge states. A peptide with a molecular mass of several thousand daltons may therefore generate peaks at much lower m/z values because each ion carries multiple charges.

Theoretical mass versus observed mass

A COA may list a theoretical molecular mass calculated from the expected sequence and an observed mass derived from the spectrum. Close agreement supports identity. However, interpretation depends on whether the report is using monoisotopic mass, average molecular weight, neutral mass, protonated ions, or a deconvoluted spectrum.

Common features in peptide mass spectra

Mass match does not equal purity

Mass spectrometry can detect a species consistent with the expected peptide even when substantial impurities are present. A spectrum showing the correct mass answers an identity question; it does not automatically show that the sample is 99% pure or that the vial contains the labeled amount.

Mass match does not always prove sequence order

Two peptides can theoretically have the same elemental composition and intact molecular mass while differing in amino-acid order. More extensive characterization—such as tandem mass spectrometry, peptide fragmentation, amino-acid analysis, comparison with a qualified reference standard, or other sequence-sensitive methods—may be required when sequence confirmation is critical.

Assay, Peptide Content, and Vial Quantity

When a label states a number of milligrams per vial, the most directly relevant analytical question is whether a quantitative test supports that content claim. A purity percentage alone does not answer it.

What makes a quantitative method credible?

A meaningful assay normally requires a calibrated method, appropriate standards, controlled sample preparation, defined units, and evidence that the procedure is fit for its intended purpose. Depending on the material and laboratory, quantitative approaches may include calibrated HPLC or UPLC, amino-acid analysis, quantitative NMR, mass-balance approaches, or other validated or scientifically justified methods.

Reference-standard potency matters

A reference standard is not always 100% peptide by mass. It may contain water, counterions, residual solvents, or other components. A well-controlled assay accounts for the assigned potency or content of the standard. Simply weighing a nominal amount of an unqualified standard can bias the result.

Gross dry weight versus net peptide content

A vial’s total dried mass may include:

• The target peptide
• Counterions such as acetate or trifluoroacetate
• Residual moisture
• Residual solvents
• Buffer components
• Bulking agents or stabilizing excipients
• Related peptide impurities

Therefore, weighing the total dried cake does not necessarily provide the net amount of target peptide.

Understand the reporting basis

Quantitative results may be reported “as is,” on an anhydrous basis, on a salt-free basis, as free peptide, as a specific salt, or after correction for purity. Those bases are not interchangeable. A credible report should state what the number represents.

One vial does not establish uniformity across an entire batch

A result from one vial describes that tested vial. It may support—but cannot by itself prove—uniformity across hundreds or thousands of vials. Confidence increases when sampling is randomized, multiple vials are tested, the filling process is controlled, and the sampling plan is justified.

Understanding Peptide Impurities

Synthetic peptides can contain process-related and degradation-related impurities. The impurity profile depends on sequence length, amino-acid composition, protecting groups, coupling efficiency, cleavage conditions, purification, storage, and formulation.

Common categories of peptide-related impurities

Unknown impurities still matter

A chromatogram may label minor peaks as “unknown.” Unknown does not necessarily mean dangerous, but it means the peak has not been fully identified. The significance depends on its amount, structure, toxicological relevance, manufacturing history, and intended use. A complete impurity-control strategy goes beyond simply adding the areas of visible minor peaks.

Related substances are not the only possible impurities

A peptide-purity method may not evaluate:

• Residual organic solvents
• Elemental impurities or metals
• Residual reagents and scavengers
• Counterion concentration
• Water content
• Microbial contamination
• Bacterial endotoxins
• Particulate matter
• Excipients or formulation errors

Each category may require a different test, such as gas chromatography for certain residual solvents, Karl Fischer titration for water, ion chromatography for counterions, inductively coupled plasma mass spectrometry for elemental impurities, or microbiological methods for bioburden and sterility-related attributes.

What a Standard Purity COA May Not Tell You

A common analytical packet includes HPLC purity and mass spectrometry identity. That combination can be valuable, but it does not cover every quality attribute.

Sterility and endotoxin are different

Sterility testing evaluates whether viable microorganisms are detected under the conditions of the test. Bacterial endotoxin testing evaluates pyrogenic lipopolysaccharides associated with Gram-negative bacteria. A material can pass one test and fail the other. Neither is established by a clear solution, a sealed vial, a high HPLC purity result, or a correct mass spectrum.

“Not detected” has a limit

When a report states “not detected,” find the method’s detection limit or reporting limit. The statement means the analyte was not detected above that method’s threshold in the tested sample. It does not necessarily mean absolute zero.

Sampling, Chain of Custody, and Batch Relevance

The quality of the laboratory method cannot compensate for an irrelevant, selectively chosen, mislabeled, or unrepresentative sample. A sophisticated report may still be misleading if the tested sample cannot be connected to the batch being sold.

Ask who selected and submitted the sample

Possible sampling models include:

• The manufacturer selected a bulk sample before filling.
• The vendor selected a finished vial.
• The laboratory received a blinded retail sample.
• An independent party purchased a sample from ordinary inventory.
• A composite sample was prepared from multiple units.

These models provide different levels of assurance. A vendor-selected “best” vial may not represent the full batch. A bulk-powder result may not establish the content or integrity of finished vials after filling and lyophilization. A finished-vial test is more directly relevant to the distributed product, but one vial still cannot prove every vial is identical.

What chain of custody should establish

• Who collected the sample
• Where it came from
• When it was collected
• How it was labeled and sealed
• How it was transported and stored
• Whether the laboratory verified package integrity
• Whether the batch identifier remained traceable throughout testing

Batch matching is essential

The batch number on the vial or product listing should match the batch number on the COA. A report for an older lot, a different concentration, a different salt form, or an unnumbered generic sample should not be presented as proof for the current batch.

Testing date matters—but freshness alone is not enough

A recent test may be preferable when degradation over time is possible, but the testing date must make sense in relation to manufacturing and distribution. A report dated before the batch existed, or a report repeatedly reused over many unrelated lots, is a major concern.

Major Peptide COA Red Flags

1. No lot number. The report cannot be confidently connected to the product in hand.
2. The lot number does not match. A valid test for another batch is not proof for the current batch.
3. Only “99% purity” is shown. No identity, amount, method, chromatogram, or supporting data is provided.
4. No laboratory can be verified. The lab name, address, report number, or contact information is missing or inconsistent.
5. No method is identified. “Purity test” is written without stating HPLC, UPLC, detector type, or method reference.
6. No units or reporting basis. A number such as “10.3” appears without mg, mg/mL, percent, area percent, or calculation basis.
7. Purity is presented as quantity. A 99% HPLC result is treated as proof of the labeled milligrams.
8. Identity relies only on retention time. No orthogonal identity method or qualified reference comparison is shown.
9. Cropped chromatograms. The time axis, baseline, integration, or smaller peaks are hidden.
10. Missing integration table. The report shows a graph but not which peaks were included or excluded.
11. Every batch has exactly the same result. Repeated identical values may indicate copied reports or template reuse.
12. Impossible or inconsistent dates. Testing occurs before sample receipt, before production, or after the report was supposedly issued.
13. Certificate edits or mismatched fonts. Formatting inconsistencies, blurred text, altered lot numbers, or layered PDF elements warrant verification.
14. A QR code proves nothing by itself. Confirm that it resolves to the issuing laboratory or a traceable report, not merely a vendor-hosted image.
15. “Pass” without a specification. The acceptance criterion is absent, vague, or appears chosen after testing.
16. Accreditation is overstated. A logo is used to imply every test is accredited even though the specific method may be outside the laboratory’s accredited scope.
17. Bulk-powder testing is presented as finished-vial testing. The report does not evaluate fill amount, vial uniformity, or post-fill handling.
18. Safety claims exceed the tests. HPLC and MS results are used to imply sterility, endotoxin control, clinical safety, or regulatory approval.

A Step-by-Step Workflow for Reviewing Any Peptide COA

Step 1: Match the document to the product

Confirm the exact peptide name, sequence or form when listed, strength, lot number, sample type, and testing date. Stop the review if the report cannot be tied to the relevant batch.

Step 2: Identify the laboratory and report

Verify the laboratory’s identity independently. Use the report number, not only the vendor’s link. When authenticity is uncertain, contact the laboratory through contact information obtained independently rather than relying only on information printed on the document.

Step 3: Separate each claim into a testable question

Write down the claims being made—identity, purity, amount, sterility, endotoxin, residual solvents, and so forth. Then identify which test on the COA addresses each claim. Any claim without a corresponding suitable method remains unsupported by that COA.

Step 4: Review methods and specifications

Determine whether the method is appropriate for its stated purpose and whether an acceptance criterion is provided. A method used for purity may not be suitable for assay. A method used for intact mass may not fully confirm sequence.

Step 5: Review the raw-data summary

For chromatography, inspect the full chromatogram, integration table, retention times, peak areas, and excluded peaks. For mass spectrometry, inspect the charge states, deconvoluted mass, expected mass, tolerance, and unexplained species.

Step 6: Check the units and calculation basis

Distinguish area percent from weight percent, concentration, total milligrams, and percent of label claim. Determine whether water, counterions, purity, or salt form were included in the calculation.

Step 7: Look for missing categories

Make a deliberate list of what was not tested. This prevents a narrow analytical result from being interpreted as a complete quality assessment.

Step 8: Evaluate sampling

Determine whether the result came from bulk powder, one finished vial, multiple vials, or an independently obtained sample. Consider whether the sample represents the material being sold.

Step 9: Compare claims with the actual evidence

Marketing language should never go beyond the test data. “Identity consistent with expected mass” is different from “fully sequence-confirmed.” “99.1% HPLC area purity” is different from “99.1% of the vial is peptide.”

Step 10: Assign a confidence level

Worked Examples

Example 1: “Purity 99.4%, MS conforms”

What it supports: The main chromatographic component represented approximately 99.4% of included integrated detected area under the stated method, and the mass result was considered consistent with the expected analyte.

What it does not establish: Labeled milligrams, sterility, endotoxin, residual solvents, water, counterion content, vial-to-vial uniformity, or suitability for human use.

Next questions: Is the chromatogram complete? How was the main peak identified? Was the sample from a finished vial? Was a quantitative assay performed?

Example 2: “Assay 96% of label claim; purity 99.2%”

Interpretation: The sample may be chromatographically clean yet contain approximately 96% of the nominal target amount under the assay method. For a nominal 10 mg claim, that might correspond to roughly 9.6 mg, depending on the calculation basis.

Important caution: Confirm whether the assay was corrected for standard potency, water, counterions, and purity, and whether the result refers to one vial or an average across several units.

Example 3: “10.8 mg total material; 98.5% HPLC purity”

Interpretation: Total dried material and chromatographic purity are not enough to calculate target peptide mass unless the composition and analytical basis are known. The material may include water, counterions, excipients, and components not measured by the HPLC method.

Example 4: “Sterility: pass; endotoxin: not tested”

Interpretation: The sterility test result applies only under the test conditions and sample plan. It does not establish endotoxin status. Endotoxins can remain even when viable bacteria are not detected.

Example 5: A current product page shows an older batch COA

Interpretation: The report may be authentic but is not evidence for the current batch unless the vendor can demonstrate that the lot is the same. Each batch can have a different impurity profile, content, and manufacturing history.

How Suppliers Can Publish More Transparent COAs

Transparency improves when a supplier publishes more than a summary number. A strong public testing packet may include:

• A clearly visible lot number that matches the product label
• The laboratory’s full identity and a verifiable report number
• Sample-received, testing, and report dates
• HPLC or UPLC method purpose and detector details
• The full chromatogram and integration table
• Mass spectrum and theoretical-versus-observed mass
• A quantitative peptide-content result when a milligram claim is made
• Clear units and calculation basis
• Specifications and actual results
• A statement identifying whether bulk powder or finished vials were tested
• The number of units sampled
• Separate results for any sterility, endotoxin, solvent, metal, or water testing
• A plain-language explanation of what each test does and does not prove

The goal should not be to create the most impressive-looking certificate. It should be to make the evidence understandable, traceable, and difficult to misinterpret.

Frequently Asked Questions

Final Takeaway

A peptide COA should not be read as a badge that says “good” or “bad.” It should be read as a collection of limited analytical claims. Identity, purity, quantity, impurity control, sterility, endotoxin, residual solvents, and batch representativeness are separate questions. The strongest evidence comes from complementary methods, clear specifications, traceable batch information, transparent raw-data summaries, appropriate standards, and representative sampling.